Literature DB >> 10937551

Osteonectin/SPARC secreted by RPE and localized to the outer plexiform layer of the monkey retina.

I R Rodríguez1, E F Moreira, D Bok, M Kantorow.   

Abstract

PURPOSE: Osteonectin/SPARC is a secreted protein that has been implicated in ocular disease. Deletion of osteonectin/SPARC causes age-onset cataract in mice and the cataractous human lens has increased expression of osteonectin/SPARC. In this study, the expression and localization of osteonectin/SPARC in the monkey retina were determined as was secretion by cultured human retinal pigment epithelial (RPE) cells.
METHODS: Adult Rhesus monkey eyes (Macaca mulatta) were dissected, and 5-mm macula and peripheral retina punches were obtained. Supernatants were collected from cultured human RPE cells. Subcellular fractionation of whole monkey retina was also performed. Osteonectin/SPARC expression and/or secretion was monitored by Northern and Western blot analyses, and localization was determined by immunocytochemistry.
RESULTS: Outside of the retina osteonectin/SPARC mRNA is broadly expressed in many human tissues. Northern blot analysis shows that in the retina osteonectin/SPARC is expressed almost exclusively by the macular RPE/choroid. Western blot analysis revealed osteonectin/SPARC in both the macula and the peripheral neural retina but only in trace amounts in the RPE/choroid. In subcellular fractions of the whole retina, osteonectin/SPARC was detected, mainly in the soluble fraction but also in the membrane and nuclear fractions. Immunohistochemical analysis localized osteonectin/SPARC specifically to the outer plexiform layer. Western blot analysis of conditioned medium from human RPE cells cultured on porous substrates indicated that osteonectin/SPARC is secreted in large amounts from both the apical and basal sides of the RPE.
CONCLUSIONS: Collectively these data provide evidence that osteonectin/SPARC is synthesized in the macular RPE, secreted, and subsequently transported to the outer plexiform layer. The expression pattern of osteonectin/SPARC in the subcellular retinal fractions is consistent with a soluble protein that is transported and internalized.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10937551      PMCID: PMC2957825     

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  27 in total

1.  Transcription of a quail gene expressed in embryonic retinal cells is shut off sharply at hatching.

Authors:  M Guermah; P Crisanti; D Laugier; P Dezelee; L Bidou; B Pessac; G Calothy
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

2.  SPARC: a Ca2+-binding extracellular protein associated with endothelial cell injury and proliferation.

Authors:  H Sage; J Decker; S Funk; M Chow
Journal:  J Mol Cell Cardiol       Date:  1989-02       Impact factor: 5.000

3.  Structure of human osteonectin based upon analysis of cDNA and genomic sequences.

Authors:  X C Villarreal; K G Mann; G L Long
Journal:  Biochemistry       Date:  1989-07-25       Impact factor: 3.162

4.  Purification and tissue distribution of a small protein (BM-40) extracted from a basement membrane tumor.

Authors:  M Dziadek; M Paulsson; M Aumailley; R Timpl
Journal:  Eur J Biochem       Date:  1986-12-01

5.  Distribution of the calcium-binding protein SPARC in tissues of embryonic and adult mice.

Authors:  H Sage; R B Vernon; J Decker; S Funk; M L Iruela-Arispe
Journal:  J Histochem Cytochem       Date:  1989-06       Impact factor: 2.479

6.  Structure and expression of osteonectin mRNA in human tissue.

Authors:  M F Young; A A Day; P Dominquez; C I McQuillan; L W Fisher; J D Termine
Journal:  Connect Tissue Res       Date:  1990       Impact factor: 3.417

7.  Molecular analysis of the cDNA for human SPARC/osteonectin/BM-40: sequence, expression, and localization of the gene to chromosome 5q31-q33.

Authors:  A Swaroop; B L Hogan; U Francke
Journal:  Genomics       Date:  1988-01       Impact factor: 5.736

8.  The extracellular glycoprotein SPARC interacts with platelet-derived growth factor (PDGF)-AB and -BB and inhibits the binding of PDGF to its receptors.

Authors:  E W Raines; T F Lane; M L Iruela-Arispe; R Ross; E H Sage
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

9.  Functional mapping of SPARC: peptides from two distinct Ca+(+)-binding sites modulate cell shape.

Authors:  T F Lane; E H Sage
Journal:  J Cell Biol       Date:  1990-12       Impact factor: 10.539

10.  Developmental and transformation-sensitive expression of the Sparc gene on mouse chromosome 11.

Authors:  I J Mason; D Murphy; M Münke; U Francke; R W Elliott; B L Hogan
Journal:  EMBO J       Date:  1986-08       Impact factor: 11.598

View more
  5 in total

1.  Loss of SPARC-mediated VEGFR-1 suppression after injury reveals a novel antiangiogenic activity of VEGF-A.

Authors:  Miho Nozaki; Eiji Sakurai; Brian J Raisler; Judit Z Baffi; Jassir Witta; Yuichiro Ogura; Rolf A Brekken; E Helene Sage; Balamurali K Ambati; Jayakrishna Ambati
Journal:  J Clin Invest       Date:  2006-02       Impact factor: 14.808

Review 2.  Secreted Protein Acidic and Rich in Cysteine in Ocular Tissue.

Authors:  Kurt Scavelli; Ayan Chatterjee; Douglas J Rhee
Journal:  J Ocul Pharmacol Ther       Date:  2015-07-13       Impact factor: 2.671

3.  Evaluation of SPARC as a candidate gene of juvenile-onset primary open-angle glaucoma by mutation and copy number analyses.

Authors:  Li Jia Chen; Pancy O S Tam; Clement C Y Tham; Xiao Ying Liang; Sylvia W Y Chiang; Oscar Canlas; Robert Ritch; Douglas J Rhee; Chi Pui Pang
Journal:  Mol Vis       Date:  2010-10-08       Impact factor: 2.367

4.  Integrated analysis of global mRNA and protein expression data in HEK293 cells overexpressing PRL-1.

Authors:  Carmen M Dumaual; Boyd A Steere; Chad D Walls; Mu Wang; Zhong-Yin Zhang; Stephen K Randall
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

5.  Increased SPARC expression in primary angle closure glaucoma iris.

Authors:  Jocelyn Chua; Li Fong Seet; Yuzhen Jiang; Roseline Su; Hla Myint Htoon; Amanda Charlton; Tin Aung; Tina T Wong
Journal:  Mol Vis       Date:  2008-10-20       Impact factor: 2.367

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.